Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

Digital_Intelligence_blog_pharma_thumbNovartis has given its support to the first online community specifically for patients affected by a rare form of pancreatic cancer.

The Pancreatic Neuroendocrine Tumor (PNET) Support Community is a peer-to-peer support community for patients and carers from around the world to share information and support.

Created by New Jersey-based agency Inspire, the community's patient group partners include the Carcinoid Cancer Foundation and the Pancreatic Cancer Action Network.

Novartis, whose interest in the area centres around Afinitor (everolimus), will be the site's corporate sponsor.

Inspire's CEO Brian Loew said: "We have seen repeatedly how online patient networks can empower people affected by rare diseases.

"We're grateful for the support of our nonprofit partners, and to Novartis, all of whom understood that PNET patients needed this kind of resource in which they can exchange information with others facing the same serious health challenges."

Group members discuss such topics as practical tips for the newly diagnosed, chemotherapy and targeted therapies, and surgical options, Inspire said.

11th July 2013

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics